GlassScriptPhysician profile
Olusegun David Asubiojo
NPI 1508444191
$3,311.71
in general payments reported to CMS, 2019-2025
20 companies · $816 in 2025
The $816 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $491 · 2023: $665 · 2024: $1,053 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $841.63 | 2022-2025 | |
| Amgen INC. | $443.14 | 2021-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $421.77 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $273.84 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $273.79 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $266.04 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $241.21 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.64 | 2024-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $77.67 | 2022-2024 | Trintellix |
| Astellas Pharma US INC | $64.57 | 2024-2025 | Veozah |
| Dexcom, INC. | $64.20 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $60.58 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $45.32 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Neos Therapeutics, LP | $35.40 | 2023 | Adzenys Xr-Odt |
| Philips North America LLC | $26.95 | 2025 | Dose Professional Services |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $22.38 | 2023 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.08 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $20.75 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2024 | Jardiance |
| Exact Sciences Corporation | $14.30 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olusegun Asubiojo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.